TY  - CHAP
AU  - Rebeca Pérez-Cabeza De Vaca
AU  - Balasubramaniyan Vairappan
AU  - Tomás Cortés Espinoza
AU  - Juan Antonio Suárez Cuenca
AU  - Cuauhtemoc Licona Cassani
AU  - Brenda Maldonado Arriaga
AU  - Chrisitan Navarro Gerrard
AU  - Diana Selene Morgan Penagos
AU  - Paul Mondragón Terán
AU  - Victoria Chagoya De Sanchez
ED  - Luis Rodrigo
ED  - Ian Martins
ED  - Xiaozhong Guo
ED  - Xingshun Qi
Y1  - 2021-04-05
PY  - 2021
T1  - Spontaneous Bacterial Peritonitis: Physiopathological Mechanism and Clinical Manifestations
N2  - This book discusses clinical advances in hepatology, with a focus on metabolic diseases and chronic hepatitis C. The development of direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection in 2010 has completely transformed the management of this disease. This transformative nature of DAA therapy underpins the goal of the World Health Organization (WHO) to eliminate HCV infection as a public health threat by 2030. The advantages of using these therapies include high efficacy (sustained virological response rate >95%) with minimal side effects, good tolerability, easy drug administration (once-daily oral dosing) and short duration of treatment (8-12 weeks). The commercialization of second-generation DAA agents due to their high effectiveness, few side-effects and pangenotypic action. This transformative nature of DAA therapy underpins the goal of the WHO to eliminate HCV infection as a public health threat by 2030.
BT  - Advances in Hepatology
SP  - Ch. 11
UR  - https://doi.org/10.5772/intechopen.96910
DO  - 10.5772/intechopen.96910
SN  - 978-1-83968-624-5
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-19
ER  -